AHOD1721/BMS CA209744 – Risk-based, response-adapted, Phase II open-label trial of nivolumab + brentuximab vedotin (N + Bv) for children, adolescents, and young adults with relapsed/refractory (R/R) CD30 + classic Hodgkin lymphoma (cHL) after

This study is designed to investigate whether the use of copanlisib is safe, feasible and beneficial to pediatric patients with solid solid tumors or lymphoma that are recurrent or refractory to standard therapy.

Principal Investigator:
Ivan Kirov, MD

Research Coordinator:
Dorian Chan, RN
(714) 509-8646



  • Clinical Trial Info
  • IRB Number: 180213
  • Sponsor: COG/BMS
  • Protocol Number: AHOD1721
  • Research Type: Adolescents and Young Adults, Recurrent/Refractory Cancer, Solid Tumors
  • Phase: II
  • Status: Active

Key Inclusion Criteria:

  • Age: 6 months – 21 years
  • Patients must have histologic verification of a solid tumor or lymphoma malignancy at diagnosis
  • Adequate bonemarrow, reanal and lver function
  • Key Exclusion Criteria:
  • Active or uncontrolled infection (National Cancer Institute (NCI)-CTCAE Grade ≥ 2).
  • History or concurrent condition of interstitial lung disease of any severity and/or severely impaired lung function
  • Diabetes mellitus.
  • Uncontrolled arterial hypertension despite optimal medical management
  • Patients with central nervous system (CNS) malignancies.

Long Live Childhood

Facebook Twitter Pinterest Instagram Snapchat LinkedIn YouTube